16.56 USD
▼-0.35-2.07%
盘后 19.10 0.00%
2026-09-15
市值
$258.67M
市盈率
—
EPS
-15.47
股息率
—
52 周区间
7.15 – 43.85
成交量
1.29M
Beta
1.49
目标价
47.23
52W 低 7.1552W 高 43.85
价格走势
公司简介
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcin...